Skip to main content

Nyxoah SA

corporate_fare Company Profile

Nyxoah SA

NYXH·NASDAQ·Industrial Applications And Services·CIK 0001857190

Nyxoah SA is a medical technology company that develops and commercializes solutions for Obstructive Sleep Apnea (OSA). The company's primary product is the Genio system, a hypoglossal neurostimulation (HGNS) therapy designed for moderate to severe OSA. This system is implanted through a single-incision procedure and is CE-Marked and FDA approved. OSA is a common sleep-disordered breathing condition linked to increased mortality risk and conditions such as cardiovascular diseases, depression, and stroke. The Genio system is a HGNS device that treats OSA by providing bilateral stimulation to maintain upper airway patency, reducing obstructive breathing events during sleep. Nyxoah SA began generating revenue from Genio system sales in Europe in July 2020. On August 8, 2025, the FDA approved the Genio system for adult patients with moderate to severe OSA, specifically those with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Sales of the Genio system in the U.S. commenced in September 2025. Approximately 425 million people globally between the ages of 30 and 69 suffer from moderate to severe OSA. In Nyxoah SA's initial target markets in Europe, an estimated 23.8 million individuals have moderate to severe OSA.

Nyxoah SA (NASDAQ:NYXH) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 22 items for NYXH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for NYXH spans 6-K, 424B5, FWP, 20-F.

Recent high-impact activity:

  • Nyxoah Wins Default Judgment Against Inspire in European Patent Case
  • Nyxoah Q3 Revenue €9.2M; New Risk Factor Flags Nasdaq $1.00 Bid-Price Delisting Threat
  • Nyxoah Cuts 2026 Revenue Guidance to €33-35M Despite 29% U.S. Sequential Growth
  • Nyxoah Taps Former Teleflex CEO Liam Kelly to Lead Next Phase
  • Nyxoah Delivers €7.7M in Preliminary Q2 Revenue as CMS Proposes 12–15% Reimbursement Boost

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$90.08M
Diluted EPS
-$2.36
Op. Cash Flow
-$68.98M
Free Cash Flow
-$69.78M
Gross Profit
$6.33M
Operating Income
-$83.48M
Cash & Equivalents
$7.87M
Debt / Equity
0.00×
Shares Outstanding
43.03M sh
Source: 20-F · filed 2026-03-26 · accession 0001104659-26-035161

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 331,332 shares in NYXH as of the October 30, 2026 settlement, a 55.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 52.4% of NYXH volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)331,332 shares as of October 30, 2026
Change vs prior period▲ 55.1%
Days to cover1.00 at avg daily volume of 337,038
Daily short volume (FINRA facilities)52.4% of 42,945 shares on November 20, 2026
5-day average short volume45.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for NYXH, detected from its recent SEC filings · based on capital-structure filings through 2026-06-23.

1 recent capital raise

Public Offering Finalized · Significant Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

NYXH files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$0.805
52-week range · as of 2026-11-05 $0.80 – $5.92
Market cap
$81.98M
Volume
97.5K (0.4× avg)
3-mo avg 223.7K
Live data · 2026-11-21 16:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NYXH - Latest Insights

NYXH
Nov 18, 2026, 2:30 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.8999
Real-time Price: $0.805 info
Change: -$0.0949 (-11%) info
Market Cap: $81.981M info
NYXH
Nov 05, 2026, 4:18 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.811
Real-time Price: $0.805 info
Change: -$0.0060 (-0.74%) info
Market Cap: $81.981M info
NYXH
Oct 20, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.805 info
Change: -$0.135 (-14%) info
Market Cap: $81.981M info
NYXH
Sep 29, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.37
Real-time Price: $0.805 info
Change: -$0.565 (-41%) info
Market Cap: $81.981M info
NYXH
Jul 09, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.67
Real-time Price: $0.805 info
Change: -$0.865 (-52%) info
Market Cap: $81.981M info
NYXH
Jun 23, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $0.805 info
Change: -$0.765 (-49%) info
Market Cap: $81.981M info
NYXH
Jun 15, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $0.805 info
Change: -$0.745 (-48%) info
Market Cap: $81.981M info
NYXH
Jun 11, 2026, 5:00 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.48
Real-time Price: $0.805 info
Change: -$0.675 (-46%) info
Market Cap: $81.981M info
NYXH
Jun 10, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $0.805 info
Change: -$0.495 (-38%) info
Market Cap: $81.981M info
NYXH
Jun 10, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.31
Real-time Price: $0.805 info
Change: -$0.505 (-39%) info
Market Cap: $81.981M info
NYXH
Jun 08, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $1.70
Real-time Price: $0.805 info
Change: -$0.895 (-53%) info
Market Cap: $81.981M info
NYXH
Jun 05, 2026, 3:53 PM EDT
Filing Type: FWP
Importance Score:
9
Price at Filing: $1.46
Real-time Price: $0.805 info
Change: -$0.655 (-45%) info
Market Cap: $81.981M info
NYXH
Jun 05, 2026, 11:25 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.58
Real-time Price: $0.805 info
Change: -$0.7736 (-49%) info
Market Cap: $81.981M info
NYXH
Jun 04, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $0.805 info
Change: -$1.67 (-67%) info
Market Cap: $81.981M info
NYXH
Jun 04, 2026, 4:07 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $0.805 info
Change: -$1.67 (-67%) info
Market Cap: $81.981M info
NYXH
Jun 04, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $0.805 info
Change: -$1.67 (-67%) info
Market Cap: $81.981M info
NYXH
May 12, 2026, 4:09 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.07
Real-time Price: $0.805 info
Change: -$2.26 (-74%) info
Market Cap: $81.981M info
NYXH
Mar 26, 2026, 4:01 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $3.09
Real-time Price: $0.805 info
Change: -$2.28 (-74%) info
Market Cap: $81.981M info
NYXH
Mar 19, 2026, 5:04 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.17
Real-time Price: $0.805 info
Change: -$2.36 (-75%) info
Market Cap: $81.981M info
NYXH
Mar 19, 2026, 4:10 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.17
Real-time Price: $0.805 info
Change: -$2.36 (-75%) info
Market Cap: $81.981M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets